New Drug Application intended for 2026, subject to generation of positive data from three U.S. clinical trials planned or in progressTotal addressable market (TAM) for ARAKODA for Human Babesiosis is ...

I am upgrading Rush Street Interactive to a buy as the company is starting to show consistent positive net income and margin gains.